Clinical Trial Update: TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating TACE plus HAIC with oxaliplatin and raltitrexed for hepatocellular carcinoma (BCLC stage C).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• Raltitrexed (Raltitrexed)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Transarterial Chemoembolization, Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN